The Challenge
An InFocus Clinical Research partner with a single product, limited resources and anxious investors was faced with an unforeseen protocol delay, requiring FDA interactions and a halt to enrollment after just 25 subjects (of a planned 125) were enrolled. Retention of intellectual capital and commitment of investigators and site staff were important to maintain momentum, restrain costs and salvage the product development.
The Solution
InFocus Clinical Research, as the selected clinical development partner, offers sponsors large and small a unique and unprecedented level of commitment conferred by its foundation – by thought leaders and leading clinical research professionals with decades of clinical development experience, committed to and passionate for the advancement of medicine.
InFocus Clinical Research offers sponsor partners a suite of organic advantages that critically salvage challenging situations, including:
- Retention of intellectual capital from project start to finish with a historical critical clinical research staff retention rate of 90% – far exceeding annual project retention rates (25%) of mass market competitors
- Utilization of InFocus Clinical Research Premier and Priority Site Network ensures, regardless of delays, partner programs remain a priority commitment
- Scientific Advisory Board engagement with KOLs and leading research sites maintains critical clinical development momentum and commitment
- Singular commitment to the development of ophthalmology products ensures clinical research staff are consistently in contact with key sites and staff throughout project delays, without draining budgets with costly project maintenance fees
The Choice
Without InFocus Clinical Research as a clinical development partner, sponsor delays are often accompanied by significant cost adjustments, dramatic turnover of study teams, a loss of momentum and loss of interest from key investigators and sites.
With InFocus Clinical Research as a clinical development partner, your product and program are ensured the greatest opportunity for success and avoidance of crippling challenges.
The Results
InFocus was able to pivot resources to other ophthalmology programs, preserve sponsor funds, streamline processes, retain the commitment of investigators and staff. Also critical, InFocus retained critical intellectual capital by being able to reengage all study resources upon relaunch, enrolling over 100 subjects in eight weeks.
